Responsiveness of the Motor Function Measure in Patients With Spinal Muscular Atrophy.
Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C and the MFM Spinal Muscular Atrophy Study Group.
Arch Phys Med Rehabil. 2013. 94(8) : 1555-61.
Assessment in 112 patients with Spinal Muscular Atrophy (SMA) aged 5.7 to 59 years of the ability of the MFM to detect changes in the progression of SMA. In patients with SMA type 2 and type 3, there was a moderate inverse relationship between age and the MFM total score. Patients with less than 6 months’ follow-up showed little score changes. Patients with a longer follow-up showed a slow deterioration (-0.9 points/y for type 2 and -0.6 points/y for type 3). Substantial responsiveness was obtained with the MFM D2 subscore (proximal and axial motricity) in patients with SMA type 2, and with the MFM D1 subscore (standing and transfers) in patients with SMA type 3.
Keywords: Clinical trial, Mobility limitation, Muscle weakness, Spinal Muscular Atrophy, Neuromuscular diseases, Rehabilitation
Articles dans les revues scientifiques
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Nagy S, Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V, Bieri O, Vuillerot C, Bonati U, Fischer D. J Vis Exp. 2019. (143), e58784. Discussion in a video format on outcome measures, including MFM, used in the trial "Treatment with L-citrulline and metformin in...
Analysis of motor and respiratory function in Duchenne muscular dystrophy patients
Luiz LC, Lima Marson FA, Almeida CCB, Contrera Toro AAD, Nucci A, Ribeiro JD. Respir Physiol Neurobiol. 2019. 262:1-11. Assessment of motor and respiratory impairment of 19 Duchenne muscular dystrophy (DMD) patients. Non-ambulatory condition was associated with worse...
Assessment of disease progression in dysferlinopathy: A 1-year cohort study
Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M,...
Disease duration and disability in dysfelinopathy can be described by muscle imaging using heatmaps and random forests.
Gómez-Andrés D, Díaz J, Munell F, Sánchez-Montáñez Á, Pulido-Valdeolivas I, Suazo L, Garrido C, Quijano-Roy S, Bevilacqua JA. Muscle Nerve. 2019. 59(4), 436-444. The manner in which imaging patterns change over the disease course and with increasing disability in...
Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?
Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, Meilleur K, Bönnemann C, Jain M. Eur J Paediatr Neurol. 2019. 23 (1), 165-170. The primary objective of this study is to establish the utility of the 2-min walk test (2MWT) in patients with...
Correlation of phenotype with genotype and protein structure in RYR1-related disorders
Todd JJ, Sagar V, Lawal TA, Allen C, Razaqyar MS, Shelton MS, Chrismer IC, Zhang X, Cosgrove MM, Kuo A, Vasavada R, Jain MS, Waite M, Rajapakse D, Witherspoon JW, Wistow G, Meilleur KG. J Neurol. 2018. 265(11), 2506-2524. Variants in the skeletal muscle ryanodine...